Purpose: The need to develop methods for studying the safety of childhood immunization schedules has been recognized by the Institute of Medicine and Department of Health and Human Services. The recommended childhood immunization schedule includes multiple vaccines in a visit. A key concern is safety of concomitant (same day) versus separate day vaccination. This paper addresses a methodological challenge for observational studies using a self-controlled design to investigate the safety of concomitant vaccination.
| INTRODUCTION
The childhood immunization schedule recommended by the Advisory Committee on Immunization Practices (ACIP) in the United States targets 14 preventable childhood diseases. 1 Although the majority of United
States parents adhere to the recommended schedule, a vocal minority have concerns regarding the number of vaccinations. Surveys reported 10-30% of parents choose to vaccinate according to alternative schedules, either refusing or delaying vaccines. [2] [3] [4] [5] [6] "Spacers" or "shot limiters"
intend for their children to receive all recommended vaccines eventually, but believe it is safer if fewer vaccines are administered on the same day. 7 Even among parents who adhere to the recommended vaccine schedule, 20% believe that delaying vaccines would be safer. [3] [4] [5] [6] 8, 9 In light of the need for comprehensive studies addressing the safety of the recommended immunization schedule, the Institute of (HHS) recommended that the Vaccine Safety Datalink (VSD) develop methods for studying safety of alternative immunization schedules. Currently, the vast majority of pre-and post-licensure evaluation of vaccine safety focuses on a specific vaccine and adverse event (AE) of interest however, there is some recent literature on safety of concomitant vaccinations in both randomized trial evaluations [10] [11] [12] and observational studies 13, 14 . Pre-licensure randomized trials are not of sufficient size to evaluate risk of uncommon adverse events following vaccination. Postlicensure studies, such as those conducted in the VSD have large observational samples, but characteristics of patients who follow the recommended schedule may differ from those who choose alternative schedules.
This paper addresses a methodological challenge for studies investigating safety of same versus separate day vaccination. In such studies, positive additive interaction would suggest it is safer for the vaccines to be spaced out and given at different visits whereas negative additive interaction would suggest that is safer to give the vaccines on the same day rather than at separate visits (Table 1) . Teasing out the effects of individual vaccines given on the same day poses significant methodological challenges. For example, measles-mumps-rubella (MMR) is recommended at 12 to 15 months, and DTaP is recommended at 15 to 18 months; therefore, timing of vaccine combination is associated with age. Baseline risk of AE in young children, and the effect of MMR on AE can also change quickly with age. [14] [15] [16] In this methodological paper, we show how this can cause bias and how to adjust for it. We re-examine the known increase in risk of seizure 7 to 10 days after MMR vaccination to illustrate a proposed process for discerning whether other vaccines in the schedule (1) independently increase the risk of AE or (2) modify risk when administered concomitantly with MMR. The methods described can be applied for other vaccines and adverse outcomes.
| MATERIALS AND METHODS
We used vaccination and electronic medical record data from Kaiser Permanente Northern California and Colorado . We identified seizure using international classification of diseases 9 th revision (ICD9) codes 780.3* or 345.* in inpatient, emergency room, and urgent care settings. To avoid contamination from effects of prior vaccination, we included vaccination dates that occurred after at least 56 days without vaccination. We restricted to vaccines administered in children 11
to 23 months. We included incident outcomes defined by ICD9 codes that occurred after at least 56 days of enrollment in the health system during which there were no recorded outcomes. We further restricted incident outcomes to those with incident vaccination dates within 56 days prior to each outcome. The 56-day threshold is similar to that used in prior studies investigating MMR and risk of seizure. 14, 16 All episodes with an incident outcome within 56 days following a valid vaccination date were included in the analysis (~2% of children contributed more than one episode). Every vaccine administered on a vaccination date was included as a same day vaccination. We categorized vaccines based on the Immunization Information Systems HL7 standard CVX code set. 17 The categories we evaluated included diphtheria-tetanus-acellular pertussis (DTaP), inactivated influenza, Haemophilus influenza type B (HIB), hepatitis A, hepatitis B, measles-mumps-rubella (MMR), pneumococcal conjugate (PCV), varicella, and inactivated poliovirus. Because use of MMRV was low in our data and the risk of seizure and fever with MMRV is known to be twice as high as the risk for MMR, we excluded vaccination episodes that contained MMRV. 16 Previous work has found the window for increased risk of seizure is 7 to 10 days post MMR vaccination. 16 We re-evaluated the known findings using the self-controlled risk interval design 18 while evaluating other vaccines for potential independent or modifying effects on risk of seizure. We included days 14 to 56 as the control window ( Figure 1 ). There is a trade-off when determining the length of the control window. Longer windows can increase power and precision but can also capture more changes within individual, such as changes in baseline risk by age. We used SAS 9.4 PROC LOGISTIC event/trials syntax to fit logistic regression models that accounted for the length of follow-up in risk and control windows. We conditioned on the unique vaccination episode to make within episode comparisons (example code in the appendix). The stratified logistic model we used is equivalent to a conditional Poisson model that has an offset term equal to log(days).
| Alternative approaches to evaluating safety of vaccinations given concomitantly with vaccine of interest
There are several approaches that could be taken to address our ques- 
KEY POINTS
When investigating safety of immunization schedules:
• It is difficult to discern whether and which vaccines increase risk of adverse events.
• Apparent modification due to confounding by true effect modifiers can suggest risk from vaccines that are actually "innocent bystanders".
• Including an interaction term between vaccines in a selfcontrolled risk interval design adds a between-person comparison, opening the door for confounding by timeinvariant characteristics.
• It is critically important to adjust for relationships between effect modifying risk factors and vaccine combination. d. Evaluate departure from additivity after adjustment Estimated departure from additivity by using the coefficients from multiplicative interaction models in step 4 by applying formulas for relative excess risk due to interaction (RERI). 19 Bootstrap for confidence intervals. All eligible seizures were included in self-controlled analyses. To capture the denominators necessary to estimate AR, we identified all vaccination dates that met the inclusion criteria for the self-controlled analysis but did not restrict to episodes with an outcome within 56 days of vaccination. We estimated the expected count of events during the risk window under the null hypothesis of no increase in risk by tallying the number of outcomes within the control window and multiplying by the ratio of person-time in the risk versus the control window. Because age is related to baseline risk of the outcome, we estimated the expected count within age categories (age in month at vaccination).
Expected #AE in risk window ¼ #AE in control window #days in risk window #days in control window
We calculated the excess number of AE observed in the risk window as the difference between observed and expected number of AE 
We took a weighted sum of the age specific attributable risk where the weights standardized the age distribution to the observed age distribution for children who received MMR without the other vaccine of interest (Equation 2).
We identified N = 2610 vaccine episodes with seizure in the risk or control intervals.
Univariate analyses
Naïve univariate analyses resulted in strong positive associations between all vaccine groups (except H1N1) and seizure (Table 2 A-1a). These results reflect the lack of adjustment for same day administration of MMR, which has a known effect on risk of seizure.
From this analysis, we know that at least 1 vaccine causes seizure but not which one(s). If nothing had been found, we could have e Separate models fit for each vaccine group, each contains 2 independent variables-vaccine group of interest and MMR.
-Sample size not sufficient Seizure (risk window 7 to 10 days, control window days 14 to 56).
stopped here. Univariate analysis restricting to dates when only a single vaccine was administered resulted in very small numbers, some too small for self-controlled analyses to be feasible (Table 2A-1b) . Similarly, the sample size for each vaccine group dropped considerably after restricting to vaccine episodes without MMR administration (Table 2A-1c) . From these analyses, we learn that MMR is associated with an increased risk of seizures, but the sample size is too small to draw inference regarding other vaccines.
Multivariable analyses
Other than MMR, DTaP had the strongest positive association with seizure after multivariable adjustment for all concomitantly administered vaccines; OR, 95% confidence interval: 1.4 (1.1, 1.7) (Table 2B- 
Evaluate whether risk is different for MMR with versus without a vaccine of interest
Children who were administered MMR and DTaP on the same day were 60% more likely to have seizure in the risk window than children who received MMR only, incidence rate ratio 1.6, 95% CI (1.2, 2.0) (Table 3 ).
Evaluate departure from multiplicity after adjustment
There was some evidence supporting divergence from multiplicity for risk of seizure with MMR and DTaP (coefficient for interaction term = 0.29, P = .124), but it was not statistically significant ( Table 4 ).
The incidence rate ratio (IRR) for same day MMR and DTaP was 4.6, whereas the multiplied incidence rate ratio for separate day MMR (Table 5 ).
Repeat analyses 3 to 5 with adjustment for relationship between age and concomitant vaccine combinations
After adjusting for the relationship between age at vaccination and the vaccine combination administered, children with same day administration of MMR and DTaP were no more likely to have seizure in the risk window than children who received MMR only, incidence rate ratio 1.2 95% CI (0.9, 1.6) ( Table 3 ). There was strong evidence that age at time of vaccination modified MMR's effect on seizure but little evidence for departure from multiplicity of effects for MMR and DTaP. For example, incidence rate ratios for same day MMR and DTaP at 12, 15, and 18 months were 3.4, 4.9 and 7.3, respectively. The corresponding multiplied risks for separate day vaccinations at each age Table 4) . Within age categories, the RERI across age categories ranged from −0.9 to 0.3. The 95% confidence intervals for each age category included 0.0, providing little support for departure from additivity within any age category; however, confidence intervals were wide (Table 5 ).
Estimate attributable risk
The age standardized attributable risk of seizure in the risk window was <1 per 10 000 for DTaP without MMR. For MMR, the age standardized attributable risk was 3 per 10 000 vaccination events, regardless of whether DTaP was administered on the same day (Table 6 ).
| Checking assumptions
In our self-controlled risk interval analyses, we assumed there were no meaningful trends in outcome incidence over the risk and control intervals (<56 days). For children between 12 and 22 months, the incidence rate for seizure was between 13 and 17 per 1000 person-years ( Figure 2) . However, the incidence rate was lower at the tail ends of the age range included in our study. For children aged 11 months or 23 months, the incidence rate was 9 to 11 seizures per 1000 personyears. In our study sample, 95% of vaccinations occurred in children 12 to 22 months, where there was little variation in baseline risk of seizure. This suggests that our assumption of constant risk of seizure within 56 days of vaccination is reasonable. In situations where strong age-related trends in seizure are observed, then age as a time-varying risk factor over the observed risk and control windows should be adjusted for.
Methods and results using fever as an outcome are available in the online appendix.
| DISCUSSION
This paper addressed a methodological challenge for evaluating the safety of concomitantly administered vaccines. We re-examined the known relationship between MMR and risk of seizure to illustrate an approach to evaluating whether other vaccines might independently DTaP had an independent effect of MMR on seizure. After accounting for the relationship between age and vaccine combination, there was no evidence for increased risk of seizure with same day administration (P > 0.3). We found similar results for the outcome fever.
We proposed a systematic multi-step approach to investigate the safety of concomitant vaccination, starting with univariate and multivariable analysis to narrow the scope and target more focused investigation into vaccines with independent effects. The initial univariate and multivariable models to target vaccine groups for deeper investigation are both a strength as well as a limitation. For example, it is possible for a vaccine to have no effect on an AE but still potentiate MMR's effect on the AE. This can be explored by proceeding to the next step of the proposed process even if nothing is found for that vaccine in the initial screen.
One issue to keep in mind is that same day exposure to a combination of vaccines could shift the true risk window for the AE. When we demonstrated that age at vaccination was not only a modifier of the effect of MMR on AE, but also a confounder due to concomitant administration of MMR and DTaP being more common in older children and the age-related increase in risk of AE associated with MMR.
When numerous risk factors are associated with vaccine combination, these could be summarized in a baseline disease risk score for adjustment of confounding. [20] [21] [22] In our example, we modeled a linear age interaction with MMR.
However, it is possible that the modifying effect of age is non-linear.
This can be explored in future work. We also imposed conservative criteria for defining incident vaccination that would exclude "spacers" whose children are vaccinated more than once within 56 days. While a washout to define incidence is necessary to distinguish the effects of vaccines administered on 1 day from proximal prior vaccinations, future studies could explore less restrictive requirements for defining incident exposure and outcome.
We have outlined a systematic approach to dissect which of several concomitantly administered vaccines is responsible for increased risk of an adverse event, while adjusting for confounding due to relationship between an effect modifying risk factor (age) and the vaccine combination recommended in immunization schedules. Immunization schedules recommend vaccines at specific ages. Vaccine associated risk of AE can change markedly in the first few years of life. We have shown that when investigating safety of concomitant vaccination, it is critically important to assess the potential for confounding by the relationship between age at vaccination and set of concomitant vaccines administered.
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